EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis

Ashton D Hall, Divya Salibindla, Luis Dubocq-Cabrera, Madeline Hunt, Lea M Rotert, Rachel S Johnson, Anna R Balog, George S Deepe, Lisa A Haglund

The American Journal of Tropical Medicine and Hygiene · 2025

DOI: 10.4269/ajtmh.24-0802 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2025. Verfasst von Ashton D Hall und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Dermatomyositis, Histoplasmosis, Lymphohistiocytosis, Hemophagocytic, Macrophage Activation Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histoplasmosis is the most common endemic mycosis in North and Central America, particularly in the Ohio and Mississippi River Valleys. Progressive disseminated histoplasmosis (PDH) occurs in ∼1 in 2,000 acute infections and may present atypically with multiorgan involvement, especially in immunocompromised hosts. We describe a case of PDH complicated by macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH) in a patient with dermatomyositis who was receiving long-term immunosuppressive therapy. She developed two uncommon manifestations of PDH: biopsy-proven cellulitis and intracellular yeasts within neutrophils on a peripheral blood smear. Diagnosis was delayed because of fungal antigen cross-reactivity and overlapping clinical and laboratory features of PDH and MAS/HLH. This case highlights the importance of early recognition, timely treatment, and coordinated multidisciplinary management. Our patient died 17 days after admission, underscoring the high mortality rate of MAS/HLH-associated histoplasmosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisHistoplasmosisLymphohistiocytosis, HemophagocyticMacrophage Activation SyndromeFemaleHumansFatal OutcomeHistoplasmaImmunocompromised HostAdult

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio.
  • Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Hall, A. D., Salibindla, D., Dubocq-Cabrera, L., Hunt, M., Rotert, L. M., Johnson, R. S., Balog, A. R., Deepe, G. S., & Haglund, L. A. (2025). Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.24-0802

Vancouver

Hall AD, Salibindla D, Dubocq-Cabrera L, Hunt M, Rotert LM, Johnson RS, et al. Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis. The American Journal of Tropical Medicine and Hygiene. 2025. doi:10.4269/ajtmh.24-0802

BibTeX
@article{Hall2025,
  author = {Hall, Ashton D and Salibindla, Divya and Dubocq-Cabrera, Luis and Hunt, Madeline and Rotert, Lea M and Johnson, Rachel S and Balog, Anna R and Deepe, George S and Haglund, Lisa A},
  title = {Progressive Disseminated Histoplasmosis with Dermatomyositis and Macrophage Activation Syndrome/Hemophagocytic Lymphohistiocytosis},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2025},
  doi = {10.4269/ajtmh.24-0802}
}
Kostenlos starten →